The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details.

The global Longevity economy is projected to reach $27 trillion in 2026 – but timing is everything: demystifying the opportunity for investors and innovators, today, is paramount to achieving this growth:

For investors, the risk of missing-out on genuine Longevity funding opportunities increases as more (and less-valid) start-ups enter the market;

For early-stage Longevity start-ups, attracting investors with a genuine Longevity focus, and the funds to finance later rounds, is super-important.

This research was conducted in June 2020 and respondents were contacted as either subscribers to Longevity.Technology or as attendees to our Longevity 2020 digital event. With a very big thank you to all 133 of them, here are some key highlights (you can download the full report free from our store):

  • We asked both investors and investees about their focus to identify the alignment between investor appetite and current market activity. Interestingly, only agetech, AI and dietary supplements align in terms of activity and investor appetite;
  • Investing directly with founders (45%) reflects the early-stage nature of the Longevity investment category – where investors will probably have previously exited successful tech and/or biotech businesses and are now applying both their expertise and funds into direct investment;
  • The majority of respondents prefer to invest early. This aligns with the current (early) stage nature of the Longevity market and we expect later-stage investors to enter the market as confidence grows;
  • 38% of respondents are grant-funded, or pre-equity investment, which indicates the early-stage nature of many Longevity research and development areas; 32% are raising or have raised series A;
  • 60% of respondents are looking to raise within the next 5 months;
  • Respondents have raised an average of $1.86m in external funding to date.

Do download the full report (completely free) from our store – we’ll run this again later in the year to identify trends.

Thanks again to all those who participated.

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...